MedTrace Logo

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

NCT06008197 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 5200

Last updated 2026-05-06

No results posted yet for this study

Summary

Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.

Conditions

Interventions

DRUG

Finerenone

Oral finerenone

DRUG

Placebo

Matching oral placebo

Sponsors & Collaborators

  • St. Luke's Hospital, Kansas City, Missouri

    collaborator OTHER

  • Bayer

    collaborator INDUSTRY

  • Colorado Prevention Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-17
Primary Completion
2027-11-30
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Brazil
  • Canada
  • Croatia
  • Czechia
  • Germany
  • Greece
  • Hungary
  • India
  • Italy
  • Lithuania
  • Malaysia
  • Mexico
  • Peru
  • Poland
  • South Korea
  • Spain
  • Sri Lanka
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06008197 on ClinicalTrials.gov